PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vacci... ( ANNAPOLIS Md. Sept. 26 /- PharmAt...)

PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program

Date:9/26/2008

ANNAPOLIS, Md., Sept. 26 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a multi-year contract for up to $83.9 million for advanced development of a third generation recombinant protective antigen (rPA) anthrax vaccine.

The objective of the government's third generation program is to develop an rPA anthrax vaccine which can be stored, transported and used without the need for a conventional cold chain - an important advantage for civilian biodefense deployment within the Strategic National Stockpile. In particular, the vaccine must maintain stability for three years at 35 C and induce protective immunity in just one or two doses.

Under the contract, PharmAthene will receive initial funding of approximately $13.2 million during a "base period" of performance. During this time the Company will be responsible for preclinical activities, including, development and qualification of assays, stability testing, toxicology studies and development of non-clinical animal models. During the base period NIAID retains the option of extending the contract under two separate options with a combined value of up to $9.7 million. Additional options covering advanced manufacturing and clinical development could bring the total potential value of the contract up to approximately $83.9 million, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government.

"We are pleased that NIAID has awarded such a significant contr
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
2. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
5. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
6. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
7. PharmAthene Reports First Quarter 2008 Financial Results
8. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
9. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
10. PharmAthene Reports Year-End 2007 Financial Results
11. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program

Post Your Comments:

PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vacci...( ANNAPOLIS Md. Sept. 26 /- PharmAt...)